KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Research & Development (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 16 years of Research & Development data on record, last reported at $10.7 million in Q4 2025.

  • For Q4 2025, Research & Development rose 89.72% year-over-year to $10.7 million; the TTM value through Dec 2025 reached $33.3 million, up 42.41%, while the annual FY2025 figure was $33.3 million, 42.41% up from the prior year.
  • Research & Development reached $10.7 million in Q4 2025 per RIGL's latest filing, up from $7.4 million in the prior quarter.
  • Across five years, Research & Development topped out at $18.3 million in Q3 2021 and bottomed at $2.5 million in Q4 2022.
  • Average Research & Development over 5 years is $9.7 million, with a median of $7.9 million recorded in 2025.
  • Peak YoY movement for Research & Development: crashed 81.21% in 2022, then soared 89.72% in 2025.
  • A 5-year view of Research & Development shows it stood at $13.3 million in 2021, then plummeted by 81.21% to $2.5 million in 2022, then grew by 27.44% to $3.2 million in 2023, then skyrocketed by 76.77% to $5.6 million in 2024, then skyrocketed by 89.72% to $10.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $10.7 million in Q4 2025, $7.4 million in Q3 2025, and $6.8 million in Q2 2025.